Evidence map›Paper›PMID 26320175›Full record

ArticleOncotarget2015

Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced homologous recombination, and a compensatory increase in non-homologous end joining.

Jason M Beckta, Seth M Dever, Nisha Gnawali, Ashraf Khalil, Amrita Sule, Sarah E Golding, Elizabeth Rosenberg, Aarthi Narayanan, Kylene Kehn-Hall, Bo Xu and 2 more

Erratum issuedOpen access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. PEAMOtecan, a novel chronotherapeutic polymeric drug for brain cancer.Journal of controlled release : official journal of the Controlled Release Society · 2020
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Jason M BecktaDepartment of Radiation Oncology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Seth M DeverDepartment of Radiation Oncology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Nisha GnawaliDepartment of Radiation Oncology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Ashraf KhalilDepartment of Radiation Oncology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Amrita SuleDepartment of Radiation Oncology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Sarah E GoldingDepartment of Radiation Oncology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Elizabeth RosenbergDepartment of Radiation Oncology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Aarthi NarayananNational Center for Biodefense and Infectious Diseases, George Mason University, Manassas, VA 20110, USA.
Kylene Kehn-HallNational Center for Biodefense and Infectious Diseases, George Mason University, Manassas, VA 20110, USA.
Bo XuCancer Research Department, Southern Research Institute, Birmingham, AL 35205, USA.
Lawrence F PovirkDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Kristoffer ValerieDepartment of Radiation Oncology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Virginia Commonwealth University · USGeorge Mason University · USSouthern Research Institute · US

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Keri R Maher · 1985 to 2026
$51.0M
VCU Neuroscience Center Core GrantP30NS047463 · NINDS · VIRGINIA COMMONWEALTH UNIVERSITY · PI POVLISHOCK, JOHN T · 2003 to 2013
$5.0M
Virginia Commonwealth University Postbaccalaureate Research Education ProgramR25GM089614 · NIGMS · VIRGINIA COMMONWEALTH UNIVERSITY · PI Rebecca Kelley Martin · 2010 to 2026
$4.9M
Repair of DNA double-strand breaks with damaged endsR01CA040615 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI POVIRK, LAWRENCE F · 1985 to 2014
$3.2M
ATM as target for malignant glioma radiosensitization.R01NS064593 · NINDS · VIRGINIA COMMONWEALTH UNIVERSITY · PI VALERIE, KRISTOFFER CARL · 2009 to 2013
$1.7M
Mechanisms of Mitotic Activation of the ATM kinaseR01CA133093 · NCI · SOUTHERN RESEARCH INSTITUTE · PI XU, BO · 2009 to 2013
$1.4M
ATM Controls Genomic Stability in Pluripotent Stem CellsF30CA171893 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI BECKTA, JASON MARK · 2012 to 2014
$101k
NCI NIH HHS F30 CA171893NCI NIH HHS P30 CA016059NCI NIH HHS R01 CA040615NCI NIH HHS R01 CA133093NCI NIH HHS R01 CA40615NIGMS NIH HHS R25 GM089614NINDS NIH HHS P30 NS047463NINDS NIH HHS R01 NS064593
6 · The paper itself

Abstract

Mutations in the breast cancer susceptibility 1 (BRCA1) gene are catalysts for breast and ovarian cancers. Most mutations are associated with the BRCA1 N- and C-terminal domains linked to DNA double-strand break (DSB) repair. However, little is known about the role of the intervening serine-glutamine (SQ) - cluster in the DNA damage response beyond its importance in regulating cell cycle checkpoints. We show that serine-to-alanine alterations at critical residues within the SQ-cluster known to be phosphorylated by ATM and ATR result in reduced homologous recombination repair (HRR) and aberrant mitosis. While a S1387A BRCA1 mutant - previously shown to abrogate S-phase arrest in response to radiation - resulted in only a modest decrease in HRR, S1387A together with an additional alteration, S1423A (BRCA12P), reduced HRR to vector control levels and similar to a quadruple mutant also including S1457A and S1524A (BRCA14P). These effects appeared to be independent of PALB2. Furthermore, we found that BRCA14P promoted a prolonged and struggling HRR late in the cell cycle and shifted DSB repair from HRR to non-homologous end joining which, in the face of irreparable chromosomal damage, resulted in mitotic catastrophe. Altogether, SQ-cluster phosphorylation is critical for allowing adequate time for completing normal HRR prior to mitosis and preventing cells from entering G1 prematurely resulting in gross chromosomal aberrations.

Indexed as

DNA End-Joining RepairHomologous RecombinationMitosisAlanineAtaxia Telangiectasia Mutated ProteinsBRCA1 ProteinCell Cycle ProteinsCell DeathCell Line, TumorCell SurvivalChromosome AberrationsDNA Breaks, Double-StrandedDNA DamageDNA RepairGlutamineHumansAlanineAtaxia Telangiectasia Mutated ProteinsATM protein, humanBRCA1 ProteinBRCA1 protein, humanCell Cycle ProteinsGlutamineMitomycinRecombinant ProteinsSerinecell cycleDNA damageDNA repairphosphorylationradiation

Identifiers

PMID26320175
PMCPMC4695017
OpenAlexW2137137765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.